Thermo Fisher Scientific Acquires The Binding Site Group

Thermo Fisher Scientific Acquires Olink Holding AB

July 10, 2024

Biotechnology

Thermo Fisher Scientific completed the acquisition of Olink Holding AB (publ) via a public cash tender offer at USD 26.00 per share/ADS, buying the proteomics company from shareholders including Summa Equity. The acquisition strengthens Thermo Fisher’s proteomics and protein-analysis capabilities, adding Olink’s high‑multiplex protein detection technology to its life‑science tools portfolio.

Thermo Fisher Scientific Acquires Brammer Bio for $1.7 Billion

March 25, 2019

Biotechnology

Thermo Fisher Scientific agreed to acquire Brammer Bio, a viral vector CDMO focused on gene and cell therapies, for approximately $1.7 billion in cash. The deal expands Thermo Fisher’s pharma services and viral vector manufacturing capabilities to support high-growth gene and cell therapy markets and brings a team of nearly 600 employees into its pharma services business.

Thermo Fisher Scientific Acquires PPD, Inc.

December 8, 2021

Healthcare Services

Thermo Fisher Scientific completed the acquisition of PPD, Inc. for $17.4 billion in cash, plus the assumption of approximately $3.0–$3.5 billion of net debt. The deal brings PPD's global clinical research and laboratory services into Thermo Fisher's Laboratory Products and Services segment, expanding Thermo Fisher's capabilities in clinical development and expected to generate approximately $125 million of synergies by year three.

Eurofins Discovery Acquires DiscoveryBioMed

July 5, 2022

Biotechnology

Eurofins Discovery has acquired DiscoveryBioMed, a Birmingham, Alabama–based contract research organization specializing in human primary- and immortalized-cell based bioassays. The acquisition strengthens Eurofins Discovery’s translational biology and human cell assay capabilities to expand its drug discovery services portfolio.

Adelis Equity Partners Becomes Majority Owner of Nordic BioSite Group

May 28, 2021

Healthcare Services

Adelis Equity Partners has acquired a majority stake in Nordic BioSite Group to accelerate the group's growth and pan‑European expansion of its life‑science research and diagnostics distribution platform. Tellacq Partners, together with the founders and management team, had built the group (including Nordic Biosite AB, Sanbio BV and Biomol GmbH); the parties did not disclose the purchase price.

Sherlock Biosciences Acquires Sense Biodetection

February 1, 2023

Biotechnology

Sherlock Biosciences has acquired Sense Biodetection to accelerate commercialization of CRISPR-enabled, instrument-free molecular diagnostics by integrating Sense’s Veros rapid, instrument-free test platform, chemistry and manufacturing capabilities into Sherlock’s platform. Terms were not disclosed; Sense is headquartered in Oxford, United Kingdom with additional facilities in Cambridge (UK) and Milford, Massachusetts.